Alaunos prices 610,399 shares at $3.36 in registered direct offering
Investment Agreement: Alaunos Therapeutics has entered into a definitive agreement to sell 610,399 shares of common stock at $3.36 per share, aiming for gross proceeds of approximately $2.0 million from the offering scheduled to close around June 24, 2025.
Use of Proceeds: The company plans to utilize the net proceeds of about $1.9 million primarily for its obesity program and general corporate purposes.
Trade with 70% Backtested Accuracy
Analyst Views on TCRT
About TCRT
About the author
4 Biotech Stocks Experiencing Decline: Momentum Scores Diminishing in the Last Week
Biotech Stocks Momentum Decline: Several biotech stocks have experienced significant declines in their Momentum scores over the past week, indicating a loss of strength in the sector.
Key Companies Affected: Notable companies like Capricor Therapeutics, Lava Therapeutics, Alaunos Therapeutics, and Champions Oncology have all reported drops in their Momentum scores due to various factors, including regulatory setbacks, financial losses, and downgrades from analysts.
PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies
PMGC Capital's Urging of Alaunos Therapeutics: PMGC Capital LLC has publicly urged Alaunos Therapeutics to accept a financing term sheet facilitated by a leading Wall Street bank, emphasizing that it represents a significant opportunity for the company and its shareholders.
Commitment to Shareholder Value: PMGC Capital remains dedicated to collaborating with Alaunos' leadership to enhance long-term shareholder value while commending the company's prudent financial management during challenging market conditions.
PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)
PMGC Capital's Acquisition: PMGC Capital LLC announced its acquisition of 83,500 shares (approximately 5.09%) in Alaunos Therapeutics, indicating a belief that the company is undervalued and has potential for growth.
Strategic Engagement Plans: PMGC Capital intends to engage with Alaunos' management to explore strategic opportunities such as mergers, acquisitions, or partnerships, while commending Alaunos for its financial stewardship.
TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q2 2024
Earnings Report: Alaunos Therapeutics reported a second quarter 2024 earnings per share of -71 cents and revenue of $4,000.
Automated Coverage: InvestorPlace Earnings utilizes TradeSmith data to automate the reporting of quarterly earnings, providing quick access to key financial figures without human intervention.
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- Domino's Pizza, Inc. Earnings Report: Domino's Pizza shares fell 11.2% after reporting lower-than-expected sales growth for the second quarter of FY24 and suspending its global net stores growth guidance.
- Stock Market Movements: Various other stocks experienced significant price changes in the mid-day session, with companies like Onconetix, Silo Pharma, Chuy's Holdings, and others seeing notable increases or decreases in their stock prices.
TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024
4 Biotech Stocks Experiencing Decline: Momentum Scores Diminishing in the Last Week
Biotech Stocks Momentum Decline: Several biotech stocks have experienced significant declines in their Momentum scores over the past week, indicating a loss of strength in the sector.
Key Companies Affected: Notable companies like Capricor Therapeutics, Lava Therapeutics, Alaunos Therapeutics, and Champions Oncology have all reported drops in their Momentum scores due to various factors, including regulatory setbacks, financial losses, and downgrades from analysts.
PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies
PMGC Capital's Urging of Alaunos Therapeutics: PMGC Capital LLC has publicly urged Alaunos Therapeutics to accept a financing term sheet facilitated by a leading Wall Street bank, emphasizing that it represents a significant opportunity for the company and its shareholders.
Commitment to Shareholder Value: PMGC Capital remains dedicated to collaborating with Alaunos' leadership to enhance long-term shareholder value while commending the company's prudent financial management during challenging market conditions.
PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)
PMGC Capital's Acquisition: PMGC Capital LLC announced its acquisition of 83,500 shares (approximately 5.09%) in Alaunos Therapeutics, indicating a belief that the company is undervalued and has potential for growth.
Strategic Engagement Plans: PMGC Capital intends to engage with Alaunos' management to explore strategic opportunities such as mergers, acquisitions, or partnerships, while commending Alaunos for its financial stewardship.
TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q2 2024
Earnings Report: Alaunos Therapeutics reported a second quarter 2024 earnings per share of -71 cents and revenue of $4,000.
Automated Coverage: InvestorPlace Earnings utilizes TradeSmith data to automate the reporting of quarterly earnings, providing quick access to key financial figures without human intervention.
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- Domino's Pizza, Inc. Earnings Report: Domino's Pizza shares fell 11.2% after reporting lower-than-expected sales growth for the second quarter of FY24 and suspending its global net stores growth guidance.
- Stock Market Movements: Various other stocks experienced significant price changes in the mid-day session, with companies like Onconetix, Silo Pharma, Chuy's Holdings, and others seeing notable increases or decreases in their stock prices.
TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024
